Abliva’s mission to become mitochondrial medicine powerhouse
Abliva’s CMO Magnus Hansson attended the 8th annual meeting of Mitochondrial Medicine – Therapeutic Development in March. The conference brings together leaders in translational...
BioInvent deepens collaboration with MSD
BioInvent has signed a new clinical collaboration and supply agreement with MSD. The agreement covers the evaluation of BioInvent’s anti-TNFR2 antibody BI-1910 in combination...
Chordate comments on Q4 and case report
Chordate Medical has published the year-end report for 2023, which showed an increase in sales compared to the previous year. The company has also...
Lipum seeks patent protecting inflammation-driven cancer treatment
Lipum has submitted an international patent application for SOL-116 as a treatment for inflammation-driven cancer. The patent application is based on the company's research...
Synact focuses on pushing forward rheumatoid arthritis project
SynAct Pharma is intent on making a turnaround after posting disappointing study results with lead asset resomelagon. The Swedish biotech is conducting a directed...
Cyxone comments on the clinical collaboration in the UK
Cyxone has entered into a research collaboration with a renowned British research group in Glasgow with the aim of conducting an exploratory phase II...
Alligator to maximise immuno-oncology innovation
With ongoing partnering discussion for the phase III trial with mitazalimab, Alligator Bioscience can put more focus on accelerating the development of ATOR-4066. To...
Asgard’s CEO on the EUR 30 million Series A financing
Asgard Therapeutics is a biotech based in Lund developing an immune "Trojan horse" to defeat cancer. The company recently announced a EUR 30 million...
Lipum has included first RA patient
Lipum recently announced that the first patient with rheumatoid arthritis has been included and dosed in ongoing phase I clinical trial with SOL-116 in...
Scandion kommenterar ytterligare positiva fas IIa-data
Scandion Oncology har meddelat uppdaterade positiva interimsresultat från den tredje och sista delen av den pågående fas IIa-studien CORIST med SCO-101 i metastaserad kolorektalcancer....